Ocular Therapeutix (OCUL) Stock Analysis & Winston Score

Ocular Therapeutix is a biotech company that makes medicines specifically for eye diseases. Its main product is IHEEZO, a gel used to numb the eye during procedures, and it also sells DEXTENZA, a tiny dissolvable insert placed inside the eye to deliver a steroid after eye surgery. Its customers are eye doctors, surgeons, and hospitals across the United States. The company makes money by selling these prescription drug products directly to healthcare providers and through specialty distributors. Ocular Therapeutix operates primarily in the US and has a pipeline of additional eye-drop and insert-based treatments in development, including treatments for conditions like wet age-related macular degeneration. Its drug-delivery technology — which slowly releases medicine inside the eye — gives it a degree of differentiation from traditional eye drops. However, the company is still spending far more than it earns, as shown by its deeply negative operating margin, so reaching profitability depends heavily on growing sales of its existing products and successfully advancing its pipeline.